Skip to Content
Home > About Us > Research and Grants Administration > Results
The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes.
This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring).
The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer.
The main purpose of this study is to compare any good and bad effects of using ABT-888 (Veliparib) (a “PARP” inhibitor) along with cisplatin to using cisplatin alone.
The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.
The purpose of this study is to learn if adding an experimental drug, veliparib (also known as ABT-888), to a usual treatment is better than the usual treatment alone.
View Additional Section Content
For more information about our research program and IRB, please contact: